Study of POLE mutation in high-risk endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial looks at a specific genetic change called POLE mutation in women with endometrial cancer that has a high risk of coming back. It may help doctors understand who could benefit from different treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman diagnosed with endometrial cancer.
- Your cancer is considered high-risk for coming back after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will look at how certain genetic changes (in the TP53 gene and in chromosome stability) affect endometrial cancer that has a specific molecular profile (pMMR/MSS and no POLE mutation). It aims to understand why these tumors behave the way they do.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This Phase 2 trial studies an added (adjuvant) treatment for early-stage uterine cancer that has a specific genetic change called POLE mutation and does not have a p53 abnormal pattern. The goal is to lower the risk of the cancer coming back after surgery.
This study follows people whose tumors have certain genetic changes in POLE or POLD1. It aims to learn more about these specific tumor mutations and how patients with them may be managed.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
Hear when a new Endometrial Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.